Cognitive Function and Anti-Estrogen Treatment Medical Journal Article Abstracts

The abstracts below have been edited.
The full abstract of the Medical Journal articles are available on Pubmed.
To obtain them, search Pubmed for &&url
Another interesting search of Pubmed is for &&url


1. J Clin Endocrinol Metab 1996 Jul;81(7):2545-9 
<b>"Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri.</b>
Sherwin BB, Tulandi T. Department of Psychology, McGill University, Montreal, Quebec, Canada.  

"These findings are consistent with those from studies on surgically menopausal women and strongly suggest that estrogen serves to maintain verbal memory in women. These results provide support for the efficacy of add-back estrogen regimens in women treated with GnRH agonists and also imply that estrogen may be important for maintaining memory in the postmenopause." 
&&url PMID: 8675575


2. Breast Cancer Res Treat 2001 Nov;64(2):165-76 
<b>Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen.</b> 
Paganini-Hill A, Clark LJ. Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, USA. annlia@juno.com 

"Our study suggests that current use of tamoxifen may adversely effect cognition. Further study of tamoxifen and cognition is needed so that healthy women considering tamoxifen for the primary prevention of breast cancer have comprehensive information about the side effects of the treatment." 
&&url PMID: 11194452


3. J Clin Oncol 2000 Jul;18(14):2695-701 
<b>Cognitive function in breast cancer patients receiving adjuvant chemotherapy. </b>
Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. 
Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada.  
    
"Cognitive differences were observed in breast cancer patients receiving adjuvant chemotherapy compared with healthy controls. These differences did not seem to be caused by significant differences in mood disturbance between the two groups. If confirmed, these results have substantial implications for informed consent, counseling, and psychosocial support of patients receiving adjuvant chemotherapy for breast cancer." 
&&url PMID: 10894868

 
4. Pharmacotherapy 1999 Aug;19(8):951-6 
<b>Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men.</b> 
Lund BC, Bever-Stille KA, Perry PJ. 
Clinical and Administrative Pharmacy Division, College of Pharmacy, University of Iowa, Iowa City 52242-1112, USA.  

"Andropause, a syndrome in aging men, consists of physical, sexual, and psychologic symptoms that include weakness, fatigue, reduced muscle and bone mass, impaired hematopoiesis, oligospermia, sexual dysfunction, depression, anxiety, irritability, insomnia, memory impairment, and reduced cognitive function. ... It is estimated that 20% of men aged 60-80 years have levels below the lower limit of normal. ... administration of testosterone to this population resulted in improvements in many areas. ... Preliminary data suggest that therapy may benefit elderly men with new-onset depression. ... [There is] potential for increased prostate cancer risk... Currently, insufficient evidence, primarily regarding psychologic safety and efficacy, exists to warrant general administration .... Further clinical investigations of this therapy in men with low testosterone levels and andropause symptoms are justified and necessary." 
&&url PMID: 10453966


5. Cancer 1999 Feb 1;85(3):640-50 
<b>Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. </b>
Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. 
The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam. 

"A number of patients who have undergone adjuvant (CMF) chemotherapy for operative primary breast carcinoma have reported impaired cognitive function, sometimes even years after completion of therapy. ... Breast carcinoma patients treated with adjuvant CMF chemotherapy have a significantly higher risk of late cognitive impairment than breast carcinoma patients not treated with chemotherapy (OR 6.4). This cognitive impairment is unaffected by anxiety, depression, fatigue, and time since treatment, and not related to the self-reported complaints of cognitive dysfunction." 
&&url PMID: 10091737 


6. Dis Mon 1998 Sep;44(9):421-546 
<b>Wellness in women after 40 years of age: the role of sex hormones and pheromones. </b>
Cutler WB, 
Genovese-Stone E. Athena Institute for Women's Wellness Chester Springs, Pennsylvania, USA. 

"All sex hormones affect physiologic systems including the cardiovascular system, bone metabolism, cognitive function, sexual response, and sexual attractiveness." "The health and well-being of women who have already had hysterectomies, with or without ovariectomies, can be improved by a recognition of the cascade of difficulties that must addressed" 
&&url PMID: 9803240 


7. J Nurse Midwifery 1998 Jul-Aug;43(4):262-72 
<b>Primary and secondary prevention strategies among older postmenopausal women.</b>
Keller C, Fullerton J, Fleury J. 
School of Nursing, University of Texas Health Science Center at San Antonio 78284, USA. 

"HRT, exercise, and nutrition are reviewed in terms of their potential benefits as primary and secondary preventive therapies against coronary heart disease, osteoporosis, breast and genital cancers, and the maintenance of cognitive function among older postmenopausal women. Lifestyle alternatives involving nutrition and exercise that offer many of the same benefits as HRT are discussed. Since both pharmacologic and lifestyle interventions offer significant benefit for primary and secondary prevention of disease and disability, each should be offered ... [and] should be sustained over the long term." 
&&url PMID: 9718881 


8. Baillieres Clin Endocrinol Metab 1997 Jul;11(2):311-40 
<b>Menopause and post-menopause.</b> 
Prelevic GM, Jacobs HS. 
Department of Medicine, University College London Medical School, UK.  

"Oestrogen therapy alleviates acute climacteric symptoms and also reduces the risk of cardiovascular disease, osteoporosis and Alzheimer's disease. ... it reduces morbidity and mortality from coronary heart disease by approximately 50%. ...Oestrogen therapy reduces the rate of post-menopausal bone loss, increases bone mineral density (BMD) and decreases fracture rate. ... The incidence of Alzheimer's disease is reduced by 50% in post-menopausal women taking oestrogen replacement. Limited clinical trials of oestrogen treatment in women with this disease have documented beneficial effects on cognitive function. The results of epidemiological studies of the effects of oestrogens on breast cancer risk are conflicting but recent evidence suggests that the risk is increased in current users after 5 years of use and among older women. In contrast, increase in the risk of venous thromboembolism is most significant within the first 12 months of therapy, strongly suggesting the importance of individual susceptibility." 
&&url PMID: 9403125